Shaping The Future
Catalyst Clinical Research Acquires Genpro
We are thrilled to announce our strategic acquisition by Catalyst Clinical Research. This collaboration marks an exciting milestone for our organization, propelling us towards expanded global reach, enhanced service offerings, and exceptional growth opportunities. We look forward to the journey ahead and the possibilities this partnership will bring.
Shared Values, Boundless Possibilities
Catalyst and Genpro share a common vision and values, which serve as the foundation for this collaboration. Our combined strengths and unique perspectives enable us to provide unparalleled value to our clients, partners, and employees. Together, we are united in our commitment to designing and delivering better clinical trials.
Commenting on the announcement, Catalyst CEO Nick Dyer said, “We are excited about this shared opportunity to expand our global footprint, scale services, and provide clients, partners, and employees with multiple growth opportunities. Our companies share similar values and will benefit from each other’s unique perspectives and capabilities. Together, we are stronger, and we will continue to inspire people to design and deliver better clinical trials.”
Genpro CEO Dr. Sachin Marulkar added, “By joining Catalyst, we will continue to expand our data science and reporting offerings, have access to more opportunities globally”
About Catalyst Clinical Research
Catalyst Clinical Research is a leading provider of specialized clinical development solutions. With offerings like Catalyst Flex and Catalyst Oncology, we cater to the diverse needs of the industry. Our team, spread across the US, the UK, Europe, India, and Australia, brings extensive expertise and a global presence to deliver exceptional results.
About Genpro Research
Genpro Research is a dynamic and forward-thinking technology and services partner dedicated to serving the pharmaceutical, biotechnology, and medical devices industry. Our expertise in data sciences, medical writing & evidence synthesis, and software development empowers organizations to enhance their clinical development and post-approval operations. By leveraging cutting-edge technologies such as Artificial Intelligence (AI) and Natural Language Processing (NLP), on our platforms like MaiA and Study Report Automation we drive innovation and deliver impactful solutions.
Revolutionizing Clinical Research with AI and NLP
At Genpro, our AI and NLP solutions revolutionize critical processes for medical writers, epidemiologists, and biostatisticians. By streamlining tasks such as search, extraction, collaboration, and reporting, we accelerate reporting for clinical development, Real World Evidence, and Medical Affairs. Through our collaboration with Catalyst, we are excited to further optimize internal processes and offer Software as a Service to our valued customers.
Benefits and Opportunities
The merger with Catalyst unlocks numerous benefits for both organizations. Catalyst gains an expanded global footprint, access to top talent in data sciences, and the opportunity to offer new solutions in centralized monitoring, data science, medical writing, and reporting. Genpro benefits from an increased capacity to meet client demands, new relationships with biopharma clients, and accelerated development of AI-enabled technology products that streamline core processes.
Join Us on this Remarkable Journey
We are honoured to embark on this journey together, driving innovation and advancing the biopharma industry. As Catalyst and Genpro, we are committed to delivering excellence, maintaining our relationship-driven focus, and upholding a culture of collaboration. Together, we will shape the future of clinical research and continue to exceed the expectations of our clients.